Axsome hosts solriamfetol investor day with expert panel covering MDD, ADHD, BED, and sleep disorders

Axsome Therapeutics, Inc.

Virtual investor event held Dec 7, 2023, featuring five physician thought leaders discussing solriamfetol.
Indications covered: MDD, ADHD, binge eating disorder, OSA/EDS (SHARP study), and shift work disorder.
Axsome management provided overview of clinical development plans for solriamfetol.
No specific clinical data, financial results, or pipeline milestones disclosed in the press release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.